divarasib + cetuximab

Divarasib + cetuximab is an investigational combination regimen targeting KRAS G12C-mutated colorectal cancer. **Divarasib** is a small molecule inhibitor selective for the KRAS G12C mutant, directly inhibiting mutant KRAS-G12C-driven oncogenic signaling. **Cetuximab** is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking EGFR-mediated activation of downstream signaling including the RAS–MAPK pathway. This combination addresses resistance mechanisms in colorectal cancer—where upregulation of EGFR signaling limits the efficacy of KRAS G12C inhibition alone—by inhibiting both the mutant KRAS G12C and EGFR signaling pathways. The regimen is currently being investigated in phase 1b clinical trials for patients with KRAS G12C-mutant colorectal cancer. Early trial results show a manageable safety profile and encouraging antitumor activity, with an objective response rate of 62.5% in inhibitor-naive patients and median progression-free survival of 8.1 months[1][2][3].

Other names

divarasib and cetuximab